Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Peter Thuss‐Patience, Peter Reichardt, Dmitry Bichev et al.|Journal of Clinical Oncology|2009Cited by 68
6504 Survial advantage for irinotecan versus best supportive care (BSC) as 2nd-line chemotherapy in gastric cancer – a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)P. Thuss-Patience, Peter Reichardt, Albrecht Kretzschmar et al.|European Journal of Cancer Supplements|2009Cited by 9